AMGEN INC
Tremor tracks 35 of its cancer trials. This is a large company with many drugs, so one trial matters less to it, and company-wide signals count for half.
Company-wide warning signs
These add points to every one of this company's trials.
- 3 insiders sold shares within a monthSince Aug 13, 2026+1.9
Trials
- AMGNAmgen12Calm
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Running, no new patientsPhase 3563 patientsMain results: Apr 2, 2030 - AMGNAmgen12Calm
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
FinishedPhase 3547 patientsMain results: Jun 20, 2025 - AMGNAmgen12Calm
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
FinishedPhase 3256 patientsMain results: Mar 26, 2025 - AMGNAmgen2Calm
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Signing up patientsPhase 3750 patientsMain results: Jun 30, 2027 - AMGNAmgen2Calm
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Running, no new patientsPhase 218 patientsMain results: Jan 6, 2026 - AMGNAmgen2Calm
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
FinishedPhase 3165 patientsMain results: Jan 25, 2024 - AMGNAmgen2Calm
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Signing up patientsPhase 215 patientsMain results: Mar 13, 2030 - AMGNAmgen2Calm
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Running, no new patientsPhase 232 patientsMain results: Mar 28, 2025 - AMGNAmgen2Calm
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Signing up patientsPhase 3750 patientsMain results: Jan 7, 2030 - AMGNAmgen2Calm
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
Running, no new patientsPhase 3145 patientsMain results: Mar 10, 2026 - AMGNAmgen2Calm
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
Running, no new patientsPhase 2252 patientsMain results: Aug 10, 2029 - AMGNAmgen2Calm
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Running, no new patientsPhase 1/2104 patientsMain results: Mar 6, 2031 - AMGNAmgen2Calm
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
Signing up patientsPhase 3400 patientsMain results: Sep 24, 2027 - AMGNAmgen2Calm
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
Not started yetPhase 3560 patientsMain results: Dec 30, 2031 - AMGNAmgen2Calm
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Running, no new patientsPhase 3350 patientsMain results: Jan 4, 2029 - AMGNAmgen2Calm
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Signing up patientsPhase 3450 patientsMain results: Sep 25, 2028 - AMGNAmgen2Calm
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
Signing up patientsPhase 324 patientsMain results: Jun 30, 2027 - AMGNAmgen2Calm
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Signing up patientsPhase 214 patientsMain results: Jul 1, 2028 - AMGNAmgen2Calm
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
Running, no new patientsPhase 2222 patientsMain results: Dec 30, 2027 - AMGNAmgen2Calm
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
FinishedPhase 3160 patientsMain results: Jul 16, 2025 - AMGNAmgen2Calm
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
FinishedPhase 1/2713 patientsMain results: May 29, 2026 - AMGNAmgen2Calm
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
Running, no new patientsPhase 3303 patientsMain results: Sep 7, 2029 - AMGNAmgen2Calm
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
FinishedPhase 312,301 patientsMain results: Jul 25, 2025 - AMGNAmgen2Calm
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Running, no new patientsPhase 261 patientsMain results: Oct 31, 2026 - AMGNAmgen2Calm
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
Running, no new patientsPhase 1/2329 patientsMain results: Nov 30, 2026 - AMGNAmgen2Calm
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Running, no new patientsPhase 1/2181 patientsMain results: Nov 24, 2027 - AMGNAmgen2Calm
Myasthenia Gravis Inebilizumab Trial
Running, no new patientsPhase 3238 patientsMain results: May 28, 2024 - AMGNAmgen2Calm
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Running, no new patientsPhase 3707 patientsMain results: Jan 2, 2029 - AMGNAmgen2Calm
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Running, no new patientsPhase 3315 patientsMain results: Jan 10, 2028 - AMGNAmgen2Calm
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Running, no new patientsPhase 3404 patientsMain results: Apr 20, 2030 - AMGNAmgen2Calm
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
FinishedPhase 1/253 patientsMain results: Feb 25, 2026 - AMGNAmgen2Calm
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Running, no new patientsPhase 3163 patientsMain results: Dec 14, 2026 - AMGNAmgen2Calm
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
Signing up patientsPhase 356 patientsMain results: Jan 31, 2029 - AMGNAmgen2Calm
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Running, no new patientsPhase 3633 patientsMain results: Jan 25, 2028 - AMGNAmgen2Calm
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Running, no new patientsPhase 3509 patientsMain results: Jan 29, 2025
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
6 sales (6 not pre-planned) · 0 purchases
- Khosla RachnaSVP, Business Development · Aug 13, 2026Sold 1,252 sharesabout $521 thousand · not pre-planned
- Khosla RachnaSVP, Business Development · Aug 11, 2026Sold 2,000 sharesabout $825 thousand · not pre-planned
- Miller DerekSVP, Human Resources · Aug 6, 2026Sold 2,069 sharesabout $833 thousand · not pre-planned
- Miller DerekSVP, Human Resources · Aug 6, 2026Sold 1,821 sharesabout $733 thousand · not pre-planned
- Grygiel Nancy A.SVP & CCO · Aug 6, 2026Sold 1,970 sharesabout $792 thousand · not pre-planned
- Grygiel Nancy A.SVP & CCO · Aug 6, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.